BRPI0410779A - heterociclos de n-acil nitrogênio como ligantes de receptores ativados por proliferador de peroxissoma - Google Patents

heterociclos de n-acil nitrogênio como ligantes de receptores ativados por proliferador de peroxissoma

Info

Publication number
BRPI0410779A
BRPI0410779A BRPI0410779-9A BRPI0410779A BRPI0410779A BR PI0410779 A BRPI0410779 A BR PI0410779A BR PI0410779 A BRPI0410779 A BR PI0410779A BR PI0410779 A BRPI0410779 A BR PI0410779A
Authority
BR
Brazil
Prior art keywords
proliferator activated
disease
peroxisome proliferator
nitrogen heterocycles
compounds
Prior art date
Application number
BRPI0410779-9A
Other languages
English (en)
Inventor
Gary Michael Ksander
Thalaththani Ralalag Vedananda
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33476920&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0410779(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0410779A publication Critical patent/BRPI0410779A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

"HETEROCICLOS DE N-ACIL NITROGêNIO COMO LIGANTES DE RECEPTORES ATIVADOS POR PROLIFERADOR DE PEROXISSOMA". Compostos da fórmula (I) provêem agentes farmacológicos que se ligam a Receptores Ativados por Proliferador de Peroxissoma (PPARs). Desse modo, os compostos da presente invenção são úteis para o tratamento de condições mediadas pela atividade do receptor de PPAR em mamíferos. Tais condições incluem dislipidemia, hiperlipidemia, hipercolesteremia, aterosclerose, hipertrigliceridemia, falência cardíaca, infarto do miocárdio, doenças vasculares, doenças cardiovasculares, hipertensão, obesidade, inflamação, artrite, câncer, doença de Alzheimer, distúrbios de pele, doenças respiratórias, distúrbios oftálmicos, doenças do intestino inflamatório, colite ulcerativa, doença de Crohn e condições onde tolerância à glicose prejudicada, hiperglicemia e resistência à insulina estão implicadas, tal como diabetes do tipo 1 e tipo 2 e Síndrome X.
BRPI0410779-9A 2003-05-20 2004-05-19 heterociclos de n-acil nitrogênio como ligantes de receptores ativados por proliferador de peroxissoma BRPI0410779A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47206703P 2003-05-20 2003-05-20
PCT/EP2004/005434 WO2004103995A1 (en) 2003-05-20 2004-05-19 N-acyl nitrogen heterocycles as ligands of peroxisome proliferator-activated receptors

Publications (1)

Publication Number Publication Date
BRPI0410779A true BRPI0410779A (pt) 2006-06-27

Family

ID=33476920

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410779-9A BRPI0410779A (pt) 2003-05-20 2004-05-19 heterociclos de n-acil nitrogênio como ligantes de receptores ativados por proliferador de peroxissoma

Country Status (26)

Country Link
US (1) US7652061B2 (pt)
EP (1) EP1638963B1 (pt)
JP (1) JP4637843B2 (pt)
KR (2) KR100909918B1 (pt)
CN (1) CN1795193B (pt)
AR (1) AR044399A1 (pt)
AT (1) ATE442365T1 (pt)
AU (1) AU2004240754B9 (pt)
BR (1) BRPI0410779A (pt)
CA (1) CA2525764C (pt)
CL (1) CL2004001169A1 (pt)
CO (1) CO5650248A2 (pt)
DE (1) DE602004023080D1 (pt)
EC (1) ECSP056175A (pt)
ES (1) ES2331131T3 (pt)
IS (1) IS8160A (pt)
MA (1) MA27777A1 (pt)
MX (1) MXPA05012465A (pt)
NO (1) NO20056056L (pt)
PE (1) PE20050157A1 (pt)
PT (1) PT1638963E (pt)
RU (1) RU2374241C2 (pt)
TN (1) TNSN05295A1 (pt)
TW (1) TW200524918A (pt)
WO (1) WO2004103995A1 (pt)
ZA (1) ZA200508905B (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1648422A4 (en) * 2003-07-28 2007-09-19 Reddys Lab Inc Dr TREATMENT AND PREVENTION OF CARDIOVASCULAR ACCIDENTS
MXPA06014572A (es) * 2004-06-24 2007-03-12 Incyte Corp Compuestos amido y su uso como farmaceuticos.
WO2006012226A2 (en) 2004-06-24 2006-02-02 Incyte Corporation N-substituted piperidines and their use as pharmaceuticals
GT200500246A (es) * 2004-09-09 2006-04-17 Combinacion de compuestos organicos
CN102036662B (zh) * 2005-06-27 2013-02-27 新树股份有限公司 利用肉豆蔻衣木脂素预防和治疗ppar介导的疾病的方法
PE20070335A1 (es) 2005-08-30 2007-04-21 Novartis Ag Benzimidazoles sustituidos y metodos para su preparacion
US20070116756A1 (en) * 2005-11-23 2007-05-24 Dr. Reddy's Laboratories Limited Stable pharmaceutical compositions
PT2402319T (pt) 2006-03-31 2017-12-11 Novartis Ag Inibidores de dgat
PE20080888A1 (es) 2006-10-18 2008-08-26 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE LA ACIL-TRANSFERASA DE ACIL-CoA-DIACIL-GLICEROL 1 (DGAT1)
EP2349484A2 (en) 2008-07-15 2011-08-03 Novartis AG Heteroaryl derivatives as dgat1 inhibitors
JP5062097B2 (ja) * 2008-08-21 2012-10-31 富士通株式会社 情報処理装置、情報処理装置の制御方法、および情報処理装置の制御プログラム
US8491927B2 (en) 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
ES2618426T3 (es) 2010-10-07 2017-06-21 Novartis Ag Nuevas formas cristalinas de la sal sódica de ácido (4-{4-[5-(6-trifluorometil-piridin-3-ilamino)-piridin-2-il]-fenil}-ciclohexil)-acético
EA201391033A1 (ru) 2011-01-13 2014-01-30 Новартис Аг Ингибиторы bace-2 для лечения метаболических расстройств
KR101569260B1 (ko) 2011-01-13 2015-11-13 노파르티스 아게 신규 헤테로시클릭 유도체 및 신경계 장애의 치료에서의 그의 용도
JP2014510782A (ja) 2011-04-14 2014-05-01 ノバルティス アーゲー グリコシド誘導体およびその使用
US8614195B2 (en) 2011-04-14 2013-12-24 Novartis Ag Glycoside derivatives and uses thereof
EA201490228A1 (ru) 2011-07-08 2014-08-29 Новартис Аг Новые производные трифторметилоксадиазола и их применение для лечения заболевания
UY34278A (es) 2011-08-25 2013-04-05 Novartis Ag Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades
US9187439B2 (en) 2011-09-21 2015-11-17 Inception Orion, Inc. Tricyclic compounds useful as neurogenic and neuroprotective agents
US9284284B2 (en) 2011-10-13 2016-03-15 Novartis Ag Oxazine derivatives and their use in the treatment of disease
CA2856334A1 (en) 2011-11-28 2013-06-06 Christina Hebach Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MA37439B1 (fr) 2012-04-27 2017-02-28 Novartis Ag Inhibiteurs de dgat1 à ponts éthers cycliques pour le traitement de troubles medies par l'acyle coa-diacylglycerol transferase 1 (dgat1).
WO2013163508A1 (en) 2012-04-27 2013-10-31 Novartis Ag Tetrahydropyran dgat1 inhibitors
EP3964507A1 (en) 2013-10-04 2022-03-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN106456628A (zh) 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
EP3157947A1 (en) 2014-06-23 2017-04-26 Novartis AG Hsa-gdf-15 fusion polypeptide and use thereof
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN114230571B (zh) 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
US20190000923A1 (en) 2015-12-22 2019-01-03 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3437651A1 (en) 2017-08-03 2019-02-06 Université de Strasbourg Peptides for treatment and prevention of nonalcoholic fatty liver disease
LT3723782T (lt) 2017-12-14 2026-02-10 Université De Strasbourg Peptidai, skirti nealkoholinės kepenų suriebėjimo ligos gydymui ir profilaktikai
WO2020110008A1 (en) 2018-11-27 2020-06-04 Novartis Ag Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder
JP7657151B2 (ja) 2018-11-27 2025-04-04 ノバルティス アーゲー 代謝性障害の処置のためのプロタンパク質コンバターゼスブチリシン／ケキシン９型（ｐｃｓｋ９）阻害剤としての環状ペプチド
UY38485A (es) 2018-11-27 2020-06-30 Novartis Ag Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación
RS64265B1 (sr) 2018-12-21 2023-07-31 Univ Strasbourg Peptidi za lečenje i prevenciju dijabetesa i povezanih poremećaja
WO2022219495A1 (en) 2021-04-12 2022-10-20 Novartis Ag 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
WO2023084449A1 (en) 2021-11-12 2023-05-19 Novartis Ag Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder
JP2025505198A (ja) 2022-02-10 2025-02-21 ノバルティス アーゲー 肥満の治療のためのｇｌｐ１受容体の活性化因子としての２－（（４－（（ｓ）－２－（４－クロロ－２－フルオロフェニル）－２－メチルベンゾ［ｄ］［１，３］ジオキソール－４－イル）ピペリジン－１－イル）メチル）－１－（（（ｓ）－オキセタン－２－イル）メチル）－１ｈ－イミダゾール誘導体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5045540A (en) * 1990-05-25 1991-09-03 Warner-Lambert Co. Amino acid derivatives with angiotensin II antagonist properties
ES2182203T3 (es) * 1997-10-31 2003-03-01 Hoffmann La Roche Derivados de d-prolina.
EP1165500A1 (en) * 1999-04-02 2002-01-02 Du Pont Pharmaceuticals Company Amide derivatives as inhibitors of matrix metalloproteinases,tnf-alpha,and aggrecanase
GB0024362D0 (en) * 2000-10-05 2000-11-22 Glaxo Group Ltd Medicaments
US7105556B2 (en) * 2001-05-30 2006-09-12 Bristol-Myers Squibb Company Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
TW200303742A (en) * 2001-11-21 2003-09-16 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
AU2004240754B2 (en) 2008-09-18
ZA200508905B (en) 2008-08-27
CN1795193B (zh) 2010-08-18
CO5650248A2 (es) 2006-06-30
KR100849747B1 (ko) 2008-07-31
CA2525764C (en) 2012-07-17
TNSN05295A1 (en) 2007-07-10
RU2005139525A (ru) 2006-08-10
WO2004103995A1 (en) 2004-12-02
JP2007501263A (ja) 2007-01-25
EP1638963A1 (en) 2006-03-29
TW200524918A (en) 2005-08-01
ES2331131T3 (es) 2009-12-22
MXPA05012465A (es) 2006-01-30
US20060135593A1 (en) 2006-06-22
EP1638963B1 (en) 2009-09-09
KR20060014054A (ko) 2006-02-14
US7652061B2 (en) 2010-01-26
KR100909918B1 (ko) 2009-07-29
MA27777A1 (fr) 2006-02-01
ATE442365T1 (de) 2009-09-15
AR044399A1 (es) 2005-09-14
AU2004240754A1 (en) 2004-12-02
RU2374241C2 (ru) 2009-11-27
CN1795193A (zh) 2006-06-28
NO20056056L (no) 2006-02-17
JP4637843B2 (ja) 2011-02-23
PE20050157A1 (es) 2005-05-17
PT1638963E (pt) 2009-11-18
KR20080007519A (ko) 2008-01-21
IS8160A (is) 2005-11-30
AU2004240754B9 (en) 2008-10-23
ECSP056175A (es) 2006-04-19
CL2004001169A1 (es) 2005-03-28
DE602004023080D1 (de) 2009-10-22
CA2525764A1 (en) 2004-12-02

Similar Documents

Publication Publication Date Title
BRPI0412380A (pt) compostos de benzenossulfonilamino e composições farmacêuticas que contêm esses compostos
MXPA05012465A (es) Heterociclos de nitrogeno n-acilo como ligandos de receptores activados por el proliferador de peroxisoma.
BR0214305A (pt) Compostos heterocìclicos e métodos de uso
BRPI0414536A (pt) compostos orgánicos
MX2009006795A (es) Compuestos que tienen tanto actividades de antagonismo de receptor de angiotensina ii como actividades activadoras de receptores activados por proliferizador de peroxisomas gamma.
CY1115547T1 (el) Ενωση αζολοκαρβοξαμιδιου ή αλας αυτης
BRPI0517947A (pt) composto de piridazina, composições e métodos
MA31118B1 (fr) Procede de preparation d'un derive de benzimidazole
ATE307798T1 (de) Glucagon antagonisten/inverse agonisten
CY1118308T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει βενζολικο παραγωγο υποκατεστημενο με γλυκοπυρανοζυλιο
MX2010004965A (es) Derivados de amida como moduladores de la sirtuina.
BRPI0518425A2 (pt) composiÇço farmacÊutica compreendendo Ácidos graxos âmega-3 e agonista e/ou antagonista ppar e composiÇço farmacÊutica em forma de dose unitÁria compreendendo fenofibrato e sistema solvente
CL2007002347A1 (es) Compuestos derivados de fenilo, piridina y quinolina; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de diabetes mellitus, trastornos en la tolerancia de la glucosa, obesidad, enfermedad de crohn, enferm
BRPI0511703B8 (pt) composto, composição farmacêutica, e, métodos de tratar diabete melito tipo 2, de retardar o início do diabete melito tipo 2, de tratar hiperglicemia, diabete ou resistência à insulina, obesidade, síndrome x, um distúrbio lipídico, aterosclerose, e uma condição
MY148434A (en) Fused bicyclic heteroaryl derivatives
BRPI0508233A (pt) derivados de isoquinolina e métodos para emprego destes
WO2009054390A1 (ja) チアゾリジンジオン化合物
BR0314475A (pt) Substituìdos 4-(indazol-3-il) fenóis como ligandos de receptor de estrogênio (er) e seu uso no tratamento de doenças inflamatórias
DK1049700T3 (da) Kemokinreceptorantagonister og fremgangsmåder til anvendelse deraf
BRPI0511527A (pt) compostos e composições como moduladores de ppar
Ammazzalorso et al. Synthesis of novel benzothiazole amides: Evaluation of PPAR activity and anti-proliferative effects in paraganglioma, pancreatic and colorectal cancer cell lines
EA200400882A1 (ru) ЗАМЕЩЁННЫЕ ПРОИЗВОДНЫЕ МЕТИЛЕНАМИДА В КАЧЕСТВЕ МОДУЛЯТОРОВ ПРОТЕИНТИРОЗИНФОСФАТАЗ ( PTPs )
BRPI0516025A (pt) 4-(heteroaril-metil e heteroaril-metil substituìda)-imidazol-2-tionas que atuam como agonistas alfa2 adrenérgicos
BRPI0510024A (pt) compostos e composições como modulares de ppar
UY27689A1 (es) Nuevos derivados de tiazol como antagonistas del receptor npy

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2412 DE 28-03-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.